spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  peginterferon alfa-2a 

 HSMN NewsFeed - 21 Apr 2017
Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2011
FDA Approves INCIVEK(TM) (telaprevir) for People with Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Mar 2011
VICTRELIS(TM) (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control
Biopharmaceuticals
 HSMN NewsFeed - 10 Aug 2010
Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment
Biopharmaceuticals
 HSMN NewsFeed - 25 Apr 2009
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2009
Newly Published Study Shows That Re-Treatment With Pegasys(R) (Peginterferon Alfa-2a) Provides Hepatitis C Patients With a Second Chance for a Cure
Biopharmaceuticals
 HSMN NewsFeed - 9 Mar 2009
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 17 Feb 2009
Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Dec 2008
European Commission Approval of New Indication for Roche's Pegasys(R) (peginterferon alfa-2a) Offers Hepatitis C Patients a Second Chance for a Cure
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Jun 2008
European Approval for Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of Treatment
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Apr 2008
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 14 Jan 2008
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Biopharmaceuticals
 HSMN NewsFeed - 26 Nov 2007
Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Nov 2007
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2007
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Biopharmacetuicals
 HSMN NewsFeed - 30 Oct 2007
Significant New Data on Roche's PEGASYS(R) and Hepatitis C Pipeline Compounds to be Featured at 58th Annual AASLD Meeting
Biopharmaceuticals
 HSMN NewsFeed - 15 Aug 2007
Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2007
Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon(R)
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2007
PEGASYS(R) Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered ''Cured''
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 21 May 2007
Data Suggest that PEGASYS(R) May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron(R)
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2007
Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C Genotypes 2 and 3
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2007
Human Genome Sciences Announces Positive Interim Results of Phase 2b Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2006
Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2006
Human Genome Sciences Reports Positive Interim Results of Phase 2 Trials of Albuferon(TM) With Ribavirin in Patients With Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2006
Customizing Treatment with PEGASYS(R) May Improve Chances for Success in Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2006
Roche Oral Polymerase Inhibitor R1626 Shows Strong Antiviral Activity in Chronic Hepatitis C Patients in Early Trial
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2006
Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating Hepatitis C Patients Who Failed Previous Combination Therapy Presented at AASLD
Biopharmaceuticals
 HSMN NewsFeed - 16 Oct 2006
Human Genome Sciences Reports Positive Interim Quality-of-Life Data From Phase 2B Trial of Albuferon(TM) with Ribavirin in Treatment-Naive Hepatitis C Patients
Biopharmaceuticals
 HSMN NewsFeed - 13 Oct 2006
Roche Advances Oral Polymerase Inhibitor into Phase II Study in Patients with Chronic Hepatitis C
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 40

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 40 additional stories matching:
peginterferon alfa-2a
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.